NICE no for Celgene's Vidaza violates Human Rights Act, say patient groups
This article was originally published in Scrip
UK patient groups have lodged an appeal against health technology appraisal body NICE's decision to decline Celgene's anticancer, Vidaza (5-azacitidine), for patients with myelodysplastic syndromes (MDS). The patient groups say the recommendations are "incompatible" with the UK's 1998 Human Rights Act.
You may also be interested in...
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.
In an exclusive interview, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
Criticism of Novartis/Avexis’s controversial lottery style managed access program for Zolgensma has come largely from Europe, while other countries in Latin America and Asia have been far more receptive.